Last reviewed · How we verify

Induction of spermatogenesis — Treatment Landscape & Competitive Intelligence

Induction of spermatogenesis (disease) competitive landscape: 2 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

2 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Induction of spermatogenesis, deduplicated by molecule. See the full disease page for line-of-therapy detail.

DrugGenericSponsorClassTargetLine of therapyFirst approval
Clomid clomifene Sanofi Estrogen Agonist/Antagonist 3-beta-hydroxysteroid-Delta(8),Delta(7)-isomerase 1967-01-01
Clomid Clomid rana alaaeldin aly ibrahim nasr 3-beta-hydroxysteroid-Delta(8),Delta(7)-isomerase, 5-hydroxytryptamine receptor 6, Adenosine receptor A3

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

  1. Sanofi · 1 drug in Induction of spermatogenesis
  2. rana alaaeldin aly ibrahim nasr · 1 drug in Induction of spermatogenesis

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Induction of spermatogenesis:

Cite this brief

Drug Landscape (2026). Induction of spermatogenesis — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/induction-of-spermatogenesis. Accessed 2026-06-10.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing